ClinicalTrials.gg
CompletedNCT00316940Updated Sep 20, 2013

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of bortezomib and samarium Sm 153 lexidronam pentasodium in Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Oncotherapeutics. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-20.

Sponsored by Oncotherapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Planned enrollment
150th of 267
36 · median 41
Started
2005
with 24 others
Phase 1
41 of 271
1 open now
Registered
35th of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 150th largest by planned enrollment of the 267 interventional ones that give a count, is one of 25 that started in 2005, is one of 41 in phase 1, and was the 35th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to radiation. Giving samarium 153 together with bortezomib may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma.

Read the detailed description

OBJECTIVES:

Primary

  • Assess the safety and tolerability (maximum tolerated dose and dose-limiting toxicity) of samarium Sm 153 lexidronam pentasodium and bortezomib in patients with relapsed or refractory multiple myeloma.

Secondary

  • Determine the response rate (combined complete response, partial response, and minimal response) in patients treated with this regimen.
  • Determine the time to response and the time to progression of disease in patients treated with this regimen.
  • Determine the progression-free survival and overall survival of patients treated with this regimen.
  • Assess the antitumor effects of this regimen in these patients.

OUTLINE: This is an open-label, dose-escalation study of samarium Sm 153 lexidronam pentasodium.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and samarium Sm 153 lexidronam pentasodium IV on day 3. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of samarium Sm 153 lexidronam pentasodium until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. The MTD of samarium Sm 153 lexidronam pentasodium is determined with 2 different doses of bortezomib.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.

03

Conditions studied

  • Multiple Myeloma and Plasma Cell Neoplasm

Keywords

  • stage I multiple myeloma
  • stage II multiple myeloma
  • stage III multiple myeloma
  • refractory multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Diagnosed with multiple myeloma by 1 of the following criteria:

    • Meets any 2 of the following major criteria:

      • Plasmacytomas on tissue
      • Bone marrow plasmacytosis (i.e., > 30% plasma cells)
      • Monoclonal immunoglobulin spike IgG > 3.5 g/dL or IgA > 2.0 g/dL by serum electrophoresis; kappa or lambda light chain excretion > 1 g by 24-hour urine protein electrophoresis
    • Plasmacytomas on tissue biopsy AND meets any 1 of the following minor criteria:

      • Presence of monoclonal immunoglobulin at a lesser magnitude than given under above major criteria
      • Lytic bone lesions
      • Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL
    • Monoclonal immunoglobulin spike IgG > 3.5 g/dL or IgA > 2.0 g/dL by serum electrophoresis; kappa or lambda light chain excretion > 1 g by 24-hour urine protein electrophoresis AND meets 1 of the following minor criteria:

      • Bone marrow plasmacytosis (i.e., 10-30% plasma cells)
      • Lytic bone lesions
    • Presence of monoclonal immunoglobulin at a lesser magnitude than given under major criteria with bone marrow plasmacytosis (i.e., 10-30% plasma cells) AND meets 1 of the following minor criteria:

      • Lytic bone lesions
      • Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL
  • , defined as a monoclonal immunoglobulin spike of ≥ 1 gm/dL by serum electrophoresis and/or a immunoglobulin spike of ≥ 200 mg by 24-hour urine protein electrophoresis or evidence of lytic bone disease OR
  • Nonmeasurable disease (i.e., patients with nonsecretory or oligosecretory multiple myeloma)
  • disease

    • Relapsed disease following a response or stable disease after prior chemotherapy (e.g., single-agent , vincristine, doxorubicin, and dexamethasone [VAD], or melphalan and prednisone [MP]) or high-dose chemotherapy
    • Refractory (i.e., failure to achieve at least complete or partial response or stable disease) to the most recent chemotherapy with or without systemic corticosteroids
  • No plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS syndrome)
  • No extramedullary myeloma

PATIENT CHARACTERISTICS:

  • performance status 60-100%
  • > 3 months
  • ≥ 1,500/mm³
  • count ≥ 75,000/mm³
  • and ALT ≤ 3 times (ULN)
  • ≤ 2 times ULN (unless clearly related to disease)
  • ≥ 30 mL/min

    • Creatinine clearance > 15 mL/min and \< 30 mL/min due to significant myelomatous involvement of kidneys allowed at discretion of investigator
  • Sodium > 130 mmol/L
  • No evidence of acute ischemia or new conduction system abnormalities
  • No myocardial infarction within the past 6 months
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective
  • No active infection
  • No severe hypercalcemia (i.e., serum calcium ≥ 14 mg/dL)
  • No New York Hospital Association class III or IV heart failure
  • No poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that would preclude study treatment
  • No known history
  • No known active or C viral infection
  • No history of allergic reaction attributable to compounds of similar chemical or biological composition to bortezomib, boron, mannitol, ethylenediaminetetramethylenephosphonic acid (EDTMP), or phosphonates
  • No peripheral neuropathy > grade 1

PRIOR CONCURRENT THERAPY:

  • At least 12 weeks since prior samarium Sm 153 lexidronam pentasodium

    • No more than 1 prior treatment
  • At least 24 weeks since prior strontium chloride Sr 89

    • No more than 1 prior treatment
  • No major surgery within the past 4 weeks
  • No chemotherapy within the past 3 weeks (6 weeks for nitrosoureas)
  • No corticosteroids (> 10 mg/day prednisone or equivalent) within the past 3 weeks
  • No immunotherapy, antibody therapy, or radiotherapy (except localized radiotherapy) within the past 4 weeks
  • No other concurrent agents
  • No concurrent corticosteroids (≥ 10 mg prednisone or equivalent)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Masking
None (open label)
Enrollment
36 participants (estimated)

Interventions

  • Radiationsamarium Sm 153 lexidronam pentasodium
06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose and dose-limiting toxicity

Secondary outcomes

  1. Response rate (complete, partial, and minimal response)

  2. Time to disease progression and time to response

  3. Progression-free and overall survival

  4. Antitumor effects

07

Study locations

4 sites
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309-0633, United States
  • Hematology-Oncology Medical Group of Fresno, Incorporated
    Fresno, California 93720, United States
  • West Hollywood, California 90069, United States
  • Center for Cancer and Blood Disorders at Suburban Hospital
    Bethesda, Maryland 20817, United States
08

References and documents

Publications

  • Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2009 Feb 1;15(3):1069-75. doi: 10.1158/1078-0432.CCR-08-1261. PubMed 19188182 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jun 2008 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2006
First posted
Apr 21, 2006
Start
Dec 2005
Primary completionActual
Jun 2008
CompletionActual
Feb 2011
Last update
Sep 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00316940
Lead sponsor
Oncotherapeutics
First posted
Apr 21, 2006
Start date
Dec 2005
Primary completion
Jun 2008
Completion
Feb 2011
Last update
Sep 20, 2013

Study contacts

James R. Berenson, MD
principal investigator · Oncotherapeutics
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion